Method for single-stage acid treatment of siliceous subterranean formations

Information

  • Patent Grant
  • 12270288
  • Patent Number
    12,270,288
  • Date Filed
    Thursday, March 24, 2022
    3 years ago
  • Date Issued
    Tuesday, April 8, 2025
    2 months ago
Abstract
Methods and compositions for treating a siliceous geologic formation are described herein. An aqueous treatment composition for treating such formations includes an acid having molecular weight less than about 200, or an ammonium or sodium salt thereof, an HF source, and from about 0.1 wt % to about 2.0 wt % of a fluoride scale inhibitor, the aqueous treatment composition having a pH from about 1.0 to about 3.0.
Description
FIELD

This disclosure relates to stimulation of hydrocarbon-containing subterranean formations. Specifically, methods of single-stage acid treatment of such formations is described herein.


BACKGROUND

Wells are generally drilled into subsurface rocks to access fluids, such as hydrocarbons, stored in subterranean formations. The subterranean fluids can be produced from these wells through known techniques. Acidic fluids are commonly injected into such formations to stimulate the formation and improve extraction of hydrocarbons from the formation. The acid dissolves, or otherwise removes, some mineral structures in the formation to improve hydrocarbon flow. In the particular case of sandstones, which contain siliceous minerals, hydrogen fluoride (HF) is used in many forms to dissolve the silica materials.


Calcium poses problems for these methods. In the case of HF treatment, calcium can precipitate as calcium fluoride, among other things. Operators therefore need methods of preventing calcium deposits from precipitating during acid treatment of formations. One such method is to treat the formation with a calcium-removing fluid prior to the acid treatment. The calcium-removing fluid dissolves calcium compounds in the formation, and when the fluid is removed, the calcium is removed or greatly reduced such that contact with acid results in, at most, only slight precipitation of calcium that does not hamper fluid conductivity.


Such methods suffer from the primary problem that the pre-treatment is not always precisely co-extensive with the acid treatment. Because the acid dissolves minerals, the acid can reach parts of the formation that were not exposed to calcium-removing fluid, resulting in calcium precipitation. Additionally, multiple stages of treatment use large volumes of treatment fluids. Methods are needed to prevent calcium precipitation during acid-treatment of hydrocarbon-containing siliceous formations. Also, reducing stages of treatment would reduce volume of treatment materials.


SUMMARY

Embodiments described herein provide a method of treating a siliceous geologic formation, the method comprising flowing an aqueous treatment composition into the formation, the aqueous treatment composition comprising an acid having molecular weight less than about 200, or an ammonium or sodium salt thereof, an HF source, and from about 0.1 wt % to about 2.0 wt % of a fluoride scale inhibitor, the aqueous treatment composition having a pH from about 1.0 to about 3.0


Other embodiments provide aqueous composition for treating hydrocarbon-containing formations, the composition comprising an acid having molecular weight less than about 200, or an ammonium or sodium salt thereof, an HF source, and from about 0.1 wt % to about 2.0 wt % of a fluoride scale inhibitor, the aqueous composition having a pH from about 1.0 to about 3.0.


Other embodiments described herein provide a method of treating a siliceous geologic formation, the method comprising obtaining an aqueous treatment composition comprising a mixture of organic acids having molecular weight less than about 200, or an ammonium or sodium salt thereof, an HF source, and from about 0.1 wt % to about 2.0 wt % of a fluoride scale inhibitor; using a mineral acid to adjust pH of the aqueous treatment composition to a range of about 1.0 to about 3.0 and flowing the pH-adjusted treatment fluid into the formation.





BRIEF DESCRIPTION OF THE DRAWINGS

Certain embodiments of the disclosure will hereafter be described with reference to the drawings, wherein like reference numerals denote like elements. It should be understood, however, that the accompanying drawings illustrate only the various implementations described herein and are not meant to limit the scope of various technologies described herein. The drawings show and describe various embodiments of the current disclosure.



FIG. 1 is a graph showing results of a core treatment using an embodiment of the treatment fluids described herein.



FIG. 2 is a graph showing results of another core treatment using an embodiment of the treatment fluids described herein.



FIG. 3 is a graph showing results of another core treatment using an embodiment of the treatment fluids described herein.



FIG. 4 is a graph showing results of another core treatment using an embodiment of the treatment fluids described herein.



FIG. 5 is a graph showing results of another core treatment using an embodiment of the treatment fluids described herein.



FIG. 6 is a graph showing results of another core treatment using an embodiment of the treatment fluids described herein.





DETAILED DESCRIPTION

In the following description, numerous details are set forth to provide an understanding of the present disclosure. It will be understood by those skilled in the art, however, that the embodiments of the present disclosure may be practiced without these details and that numerous variations or modifications from the described embodiments may be possible.


Methods of treating a hydrocarbon formation to enhance recovery of hydrocarbons from the formation are described herein. The methods herein comprise treating the formation with a low pH acid solution containing a fluoride scale inhibitor. The fluoride scale inhibitor interrupts crystallization of fluoride deposits resulting from reaction of the acid solution with formation materials. The acid solution contains hydrogen fluoride (HF), hydrofluoric acid, and/or a source thereof, to dissolve and/or remove clay and other siliceous materials that can reduce fluid flow with the formation. Other acids, such as hydrochloric acid or other mineral acids and organic acids can also be added to bring acidity of the solution to a target or into a target range. The treatment fluids described herein have pH of, or adjusted to, about 1.0 to about 3.0, such as about 1.5 to about 2.5, for example about 2.0. The treatment methods and compositions described herein can be used beneficially without the need for an acid preflush in most cases.


The scale inhibitors used herein are a phosphonic acid, a phosphoric acid, a phosphonate, a phosphate, a polyacrylamide, a phosphonated polyetheramine, a salt of an acrylamido-methyl propane sulfonate/acrylic acid copolymer (AMPS/AA), phosphinated maleic copolymer (PHOS/MA), a salt of a polymaleic acid/acrylic acid/acrylamido-methyl propane sulfonate terpolymer (PMA/AMPS), organophosphonates and derivatives thereof, including hydroxyethylidene diphosphonic acid (HEDP) or salts thereof, 2-phosphonobutane-1,2,4-tricarboxylic acid (PBTC) or salts thereof, amino trimethylene phosphonic acid (ATMP) or salts thereof, diethylene triamine penta (methylene phosphonic acid) (DTPMPA) or salts thereof, 2-hydroxy phosphonoacetic acid (HPAA) or salts thereof, polyamino polyether methylene phosphonic acid (PAPEMP), bis(hexamethylene triamine penta (methylene phosphonic acid)) (BHMTPMP) or salts thereof, hydroxyethylamino-di(methylene phosphonic acid) (HEMPA) or salts thereof, ethylene diamine tetra (methylene phosphonic acid) (EDTMPA) or salts thereof, hexamethylenediaminetetra (methylenephosphonic Acid) (HMDTMPA) or salts thereof, phosphonated polyetheramine, a phosphate ester, or a mixture of any of the listed materials. Salts can be ammonium salts, sodium salts, lithium salts, or mixtures thereof.


The scale inhibitors herein inhibit the formation of metal ion-containing precipitation, such as calcium, aluminum, magnesium, ferric, et al, particularly fluoride precipitates. In sandstone acid treatment, calcium fluoride is the major precipitation causing damage when calcium-containing materials exist in the formation. The scale inhibitors herein prevent the formation of calcium fluoride precipitate and then eliminate the potential damage to the formation. The efficacy of the scale inhibitors depends on amount of scale inhibitor used and formation conditions (temperature, composition). The scale inhibitor is used at a concentration of 0.1 to 2% by weight in the treatment fluid. These scale inhibitors work to limit precipitation in the pH range of about 1.0 to about 3.0, such as about 1.5 to 2.5, for example about 2.0. Outside that pH range, the precipitation limiting function of the scale inhibitors is diminished.


The treatment fluid typically contains HF, or a source thereof such as ammonium bifluoride, and may contain other acids to bring pH to a target or within a target range. Acids used herein are typically simple acids, and/or salts thereof, having molar mass of about 200 Daltons or less. The acids can be organic and/or inorganic, and the organic acids can be substituted with halogen atoms such as fluorine, chlorine, bromine, and iodine. Examples include HCl, formic acid, acetic acid, chloroacetic acid, citric acid, phosphoric acid, perchloric acid, nitric acid, hydroiodic acid, iodic acid, uric acid, sulfonic acid, lactic acid, glycolic acid, glyceric acid, sulfamic acid, methylsulfamic acid, tartaric acid, succinic acid, fumaric acid, butyric acid, valeric acid, isovaleric acid, oxalic acid, malic acid, maleic acid. Substituted versions, for example isomers or versions of the above acids having heteroatoms such as sulfur, nitrogen, phosphorus, silicon, and the like, for example amino acids or acid amides, or other acid derivatives of any of the listed acids can also be used. Ammonium, sodium, or lithium salts thereof can also be included.


The treatment fluids herein can include other ingredients, such as Brønsted acids, corrosion inhibitors, mutual solvents, clay control agents, wetting agents, iron control agents, chelating agents, and fluid loss additives. Diversion control materials, such as ball sealers and particulate materials, can also be added to the treatment fluid. Particulate materials that can be included in the treatment fluid include polymers and copolymers of lactide, glycolide, amide, phosphate, and mixtures thereof, polyethyleneterephthalate (PET); polybutyleneterephthalate (PBT); polyethylenenaphthalenate (PEN); partially hydrolyzed polyvinyl acetate; polyacrylamide, polymethacrylanlide and derivatives, combinations, or mixtures thereof, any of which may be degradable or soluble. Chelants that can be used include maleic acid, tartaric acid, citric acid, nitrilotriacetic acid, hydroxyethyliminodiacetic acid, hydroxyethylethylenediaminetetraacetic acid, ethylenediaminetetraacetic acid, cyclohexylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, ammonium salts thereof, lithium salts thereof, sodium salts thereof, and mixtures thereof.


Other additives that can be used include fluoride binding agents, such as boric acid and aluminum chloride, inhibitors for precipitation of fluorosilicate and fluoroaluminate salts, and surfactants, which may be viscoelastic surfactants and/or other surfactants. Other additives that can be used include permanent clay stabilizers, non-emulsifiers, corrosion inhibitors, friction reducers, iron control agents, diverting agents, or fluid-loss control agents. These additives can be used alone or in any combination in the treatment fluids described herein.


Example 1

A treatment fluid of 5 wt % citric acid, 5 wt % lactic acid, 0.5 wt % fluoride scale inhibitor, 0.5 wt % ammonium bifluoride, 3 wt % clay control agent, 0.18 wt % iron control agent, 10 wt % mutual solvent, and 0.5 wt % corrosion inhibitor was used to treat Berea Gray core at 160° F. The Berea sandstone core (1″ diameter and 6″ length) was tested in a Formation Response Tester Instrument, under a confining pressure of 2000 psi in a Viton sleeve and a back pressure of 600 psi. The Berea core was pre-saturated with 5 wt % NH4Cl solution. The initial permeability of the Berea core (ki) was measured by flowing 5 wt % NH4Cl solution in the injection direction. Then 10 pore volumes of the treatment fluid were subsequently injected in the injection direction at 2 mL/min. During the acid injection, samples of effluent were collected for each pore volume, and were analyzed by inductively-coupled plasma (ICP) optical emission spectroscopy. The returned permeability (kf) was measured by injecting 5 wt % NH4Cl in the injection and product directions. Five pore volumes of the effluent were collected for ICP analysis. The concentrations of several metal ions in the effluent samples were plotted vs. injected pore volume in FIG. 1. The acid treatment led to a permeability ratio (kf/ki) of 144%, indicating that the Berea core was stimulated by this treatment fluid with a 44% permeability increase. The ICP plot in FIG. 1 shows that high concentration of calcium was maintained in the solution, indicating no fluorite precipitation. Moreover, the high concentrations of silicon and aluminum ions in the solution indicate that aluminosilicate materials of the core were efficiently dissolved and maintained in the solution with little or no precipitation.


Example 2

The treatment fluid of 5 wt % citric acid, 5 wt % lactic acid, 0.5 wt % scale inhibitor, 0.5 wt % ammonium bifluoride, 3 wt % clay control agent, 0.18 wt % iron control agent, 10 wt % mutual solvent, and 0.5 wt % corrosion inhibitor, the same treatment fluid used in Example 1, was used to treat a Bandera Gray core at 160° F. using the same procedure as in Example 1. The ICP results were plotted in FIG. 2. Treatment of the Bandera Gray core led to a permeability ratio of 142%. The high concentrations of calcium, aluminum, and silicon ions in FIG. 2 again indicate efficient dissolution of calcium-containing materials and aluminosilicates during the treatment.


Example 3

The treatment fluid of 5 wt % citric acid, 5 wt % lactic acid, 0.5 wt % scale inhibitor, 1 wt % ammonium bifluoride, 3 wt % clay control agent, 0.18 wt % iron control agent, 10 wt % mutual solvent, and 0.5 wt % corrosion inhibitor, the same treatment fluid used for Examples 1 and 2, was used to treat a Bandera Gray core at 300° F. This treatment of Bandera Gray core led to a permeability ratio (kf/ki) of 408%. The high concentrations of calcium, aluminum, and silicon ions in FIG. 3 indicate efficient dissolution of calcium-containing materials and aluminosilicates during the acid treatment. Example 2 and 3 illustrate the effect of temperature on use of the treatment fluids described herein


Example 4

A treatment fluid of 5 wt % citric acid, 5 wt % lactic acid, 0.25 wt % scale inhibitor, 1 wt % ammonium bifluoride, 3 wt % clay control agent, 0.18 wt % iron control agent, and 0.5 wt % corrosion inhibitor was used to treat a Berea Gray at 160° F. This treatment fluid uses half the concentration of scale inhibitor, relative to Examples 1-3, and uses no mutual solvent. This treatment led to a permeability ratio (kf/ki) of 112%. The high concentrations of calcium, aluminum, and silicon ions in FIG. 4 indicate efficient dissolution of calcium-containing materials and aluminosilicates during the treatment. Comparing the results of Example 4 to those of Examples 1 and 2, it is thought that the reduced quantity of scale inhibitor in this treatment fluid allowed more precipitation of fluorides, resulting in less permeability, but an increase in permeability nonetheless.


Example 5

A treatment fluid of 10 wt % organic acid blend, 2 wt % HCl, 0.5 wt % scale inhibitor, 0.5 wt % ammonium bifluoride, 3 wt % clay control agent, 0.18 wt % iron control agent, and 0.5 wt % corrosion inhibitor was used to treat Berea Gray at 250° F. This treatment fluid uses a small amount of HCl in addition to other acids. This treatment led to a permeability ratio (kf/ki) of 158%. The high concentrations of calcium, aluminum, and silicon ions in FIG. 5 indicate efficient dissolution of calcium-containing materials and aluminosilicates during the acid treatment.


Example 6

A treatment fluid of 10 wt % organic acid blend, 2.2 wt % HCl, 0.5 wt % scale inhibitor, 1 wt % ammonium bifluoride, 3 wt % clay control agent, 0.18 wt % iron control agent, and 0.5 wt % corrosion inhibitor was used to treat Berea Gray at 200° F. The acid treatment led to a permeability ratio (kf/ki) of 121%. The high concentrations of calcium, aluminum, and silicon ions in FIG. 6 indicate efficient dissolution of calcium-containing materials and aluminosilicates during the acid treatment.


In Examples 1-4 above, the treatment fluid uses substantially equal weights of citric and lactic acid as an acid blend. In these Examples, the weight ratio of citric to lactic acid in the treatment fluid could range from 3:7 to 7:3. Thus, for example, instead of 5 wt % citric acid and 5 wt % lactic acid, 4 wt % citric acid and 6 wt % lactic acid could be used, 3 wt % citric acid and 7 wt % lactic acid could be used, 6 wt % citric acid and 4 wt % lactic acid could be used, and 7 wt % citric acid and 3 wt % lactic acid could be used. For Examples 5 and 6 above, the 10 wt % organic acid could be a single organic acid, of any of the acids described herein, or any mixture of the organic acids described herein.


The treatment fluids described herein can be used, in some cases, to perform an acid treatment of a sandstone formation using only one stage of treatment. Because the use of fluoride scale inhibitor reduces the formation of fluoride scales in the formation during the acid treatment, the single stage treatment can be effective in removing calcium, aluminum, and silicon debris from the formation without creating diversions that can reduce the effectiveness of the acid treatment. Single-stage acid treatment of sandstone formations reduces the time to perform the treatment and reduces the volume of treatment fluid used for the treatment. Reduced volume of treatment fluid also reduces the volume of any flowback fluid handling.


Although the preceding description has been described herein with reference to particular means, materials and embodiments, it is not intended to be limited to the particulars disclosed herein; rather, it extends to all functionally equivalent structures, methods, and uses, such as are within the scope of the appended claims.

Claims
  • 1. A method of treating a siliceous geologic formation, the method comprising: injecting an aqueous treatment composition into the siliceous geologic formation, the aqueous treatment composition comprising an acid mixture comprising acids having molecular weight between 36 and 200 Daltons, a hydrofluoric acid (HF) source, and from 0.1 wt % to 2.0 wt % of a fluoride scale inhibitor, the aqueous treatment composition having a pH from 1.0 to 3.0, wherein the acid mixture comprises a first organic acid and a second organic acid, and wherein a weight ratio of the first organic acid to the second organic acid is between 3:7 to 7:3.
  • 2. The method of claim 1, wherein the fluoride scale inhibitor is a phosphonate.
  • 3. The method of claim 1, wherein injecting the aqueous treatment composition into the siliceous geologic formation is an only stage of acid treatment performed on the siliceous geologic formation.
  • 4. The method of claim 1, wherein the first organic acid is citric acid and the second organic acid is lactic acid.
  • 5. The method of claim 1, wherein the acid mixture comprises a mineral acid.
  • 6. The method of claim 1, further comprising adjusting pH of the aqueous treatment composition using a mineral acid.
  • 7. The method of claim 2, wherein the phosphonate is an organophosphonate or derivative thereof.
  • 8. The method of claim 5, wherein the mineral acid is HCl.
  • 9. The method of claim 8, wherein the first organic acid is citric acid and the second organic acid is lactic acid.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Patent Application Ser. No. 63/166,072 filed Mar. 25, 2021, which is entirely incorporated herein by reference.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2022/021630 3/24/2022 WO
Publishing Document Publishing Date Country Kind
WO2022/204339 9/29/2022 WO A
US Referenced Citations (77)
Number Name Date Kind
4848467 Cantu Jul 1989 A
4957165 Cantu Sep 1990 A
4986355 Casad Jan 1991 A
5096618 Frenier Mar 1992 A
5529125 Di Lullo Arias Jun 1996 A
5979557 Card Nov 1999 A
6435277 Qu Aug 2002 B1
6703352 Dahayanake Mar 2004 B2
7036587 Munoz, Jr. May 2006 B2
7059414 Rae Jun 2006 B2
7119050 Chang Oct 2006 B2
7182136 Dalrymple Feb 2007 B2
7192908 Frenier Mar 2007 B2
7219731 Sullivan May 2007 B2
7237608 Fu Jul 2007 B2
7265079 Willberg Sep 2007 B2
7299870 Garcia-Lopez de Victoria Nov 2007 B2
7380600 Willberg Jun 2008 B2
7380602 Brady Jun 2008 B2
7482311 Willberg Jan 2009 B2
7506689 Surjaatmadja Mar 2009 B2
7565929 Bustos Jul 2009 B2
7575054 Fuller Aug 2009 B2
7666821 Fu Feb 2010 B2
8016034 Glasbergen Sep 2011 B2
8109335 Luo Feb 2012 B2
8167043 Willberg May 2012 B2
8312929 Frenier Nov 2012 B2
8316941 Frenier Nov 2012 B2
8618026 Ezell Dec 2013 B2
8714249 Tang May 2014 B1
8936086 Liang Jan 2015 B2
8973659 Karadkar Mar 2015 B2
9034806 Gurmen May 2015 B2
9670399 Reyes Jun 2017 B2
10280362 Purdy May 2019 B2
10329476 Purdy Jun 2019 B2
10590336 Purdy Mar 2020 B2
10738237 Beuterbaugh Aug 2020 B2
10753001 Purdy Aug 2020 B2
10822535 Purdy Nov 2020 B2
10947123 Purdy Mar 2021 B2
10982133 Purdy Apr 2021 B2
11098241 Purdy Aug 2021 B2
11168246 Purdy Nov 2021 B2
11370961 Purdy Jun 2022 B2
11447692 Purdy Sep 2022 B2
11708526 Al-Harbi Jul 2023 B2
20030134751 Lee Jul 2003 A1
20040177960 Chan Sep 2004 A1
20040254079 Frenier Dec 2004 A1
20050016731 Rae Jan 2005 A1
20060102349 Brady May 2006 A1
20070235189 Milne Oct 2007 A1
20080139412 Fuller Jun 2008 A1
20080146465 Fu Jun 2008 A1
20090042748 Fuller Feb 2009 A1
20090075844 Ke Mar 2009 A1
20090233819 Fuller Sep 2009 A1
20100230106 Milne Sep 2010 A1
20130079260 Frenier Mar 2013 A1
20160264849 Oliveira Sep 2016 A1
20160272879 Reddy Sep 2016 A1
20190345807 Purdy Nov 2019 A1
20200165511 Nino-Penaloza May 2020 A1
20200263080 Purdy Aug 2020 A1
20200317516 Purdy Oct 2020 A1
20200318009 Purdy Oct 2020 A1
20210189226 Purdy Jun 2021 A1
20210189855 Purdy Jun 2021 A1
20210198561 Purdy Jul 2021 A1
20210230476 Purdy Jul 2021 A1
20210388265 Purdy Dec 2021 A1
20220049156 Purdy Feb 2022 A1
20220089938 Purdy Mar 2022 A1
20220267178 Purdy Aug 2022 A1
20240101891 Vidma Mar 2024 A1
Foreign Referenced Citations (2)
Number Date Country
2530325 Mar 2009 CA
2024026137 Feb 2024 WO
Non-Patent Literature Citations (7)
Entry
Search Report and Written Opinion of International Patent Application No. PCT/US2022/021630 dated Jul. 1, 2022, 10 pages.
Search Report and Written Opinion of International Patent Application No. PCT/US2023/029075 dated Nov. 15, 2023, 9 pages.
Nelson, P. H., “Pore-throat sizes in sandstones, tight sandstones, and shales”, AAPG Bulletin, 2009, 93(3), pp. 329-340.
Gidley, J. L., “Acidizing Sandstone Formations: A Detailed Examination of Recent Experience”, SPE 14164, presented at the 60th Annual Technical Conference and Exhibition of the Society of Petroleum Engineers, held in Las Vegas, NV, 1985, 11 pages.
McLeod et al., “Sandstone Acidizing”, Reservoir Stimulation Book, Section 18-8, pp. 1-28.
Kashif, M. et al., “Pore Size Distribution, Their Geometry and connectivity in deeply buried Paleogene Es1 sandstone reservoir, Nanpu Sag, East China”, Petroleum Science, 2019, 16, pp. 981-1000.
Office Action issued in U.S. Appl. No. 18/505,445 dated Sep. 4, 2024, 14 pages.
Related Publications (1)
Number Date Country
20240159135 A1 May 2024 US
Provisional Applications (1)
Number Date Country
63166072 Mar 2021 US